|
1
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
2
|
Polyak K and Weinberg RA: Transitions
between epithelial and mesenchymal states: acquisition of malignant
and stem cell traits. Nat Rev Cancer. 9:265–273. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thiery JP: Epithelial-mesenchymal
transitions in tumour progression. Nat Rev Cancer. 2:442–454. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mani SA, Guo W, Liao MJ, et al: The
epithelial-mesenchymal transition generates cells with properties
of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kalluri R and Neilson EG:
Epithelial-mesenchymal transition and its implications for
fibrosis. J Clin Invest. 112:1776–1784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee JM, Dedhar S, Kalluri R and Thompson
EW: The epithelial-mesenchymal transition: new insights in
signaling, development, and disease. J Cell Biol. 172:973–981.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hollier BG, Evans K and Mani SA: The
epithelial-to-mesenchymal transition and cancer stem cells: a
coalition against cancer therapies. J Mammary Gland Biol Neoplasia.
14:29–43. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Iwatsuki M, Mimori K, Yokobori T, et al:
Epithelial-mesenchymal transition in cancer development and its
clinical significance. Cancer Sci. 101:293–299. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Frederick BA, Helfrich BA, Coldren CD,
Zheng D, Chan D, Bunn PA Jr and Raben D: Epithelial to mesenchymal
transition predicts gefitinib resistance in cell lines of head and
neck squamous cellcarcinoma and non-small cell lung carcinoma. Mol
Cancer Ther. 6:1683–1691. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Uramoto H, Iwata T, Onitsuka T, Shimokawa
H, Hanagiri T and Oyama T: Epithelial-mesenchymal transition in
EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res.
30:2513–2517. 2010.PubMed/NCBI
|
|
11
|
Rho JK, Choi YJ, Lee JK, et al: Epithelial
to mesenchymal transition derived from repeated exposure to
gefitinib determines the sensitivity to EGFR inhibitors in A549, a
non-small cell lung cancer cell line. Lung Cancer. 63:219–226.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang W, Feng M, Zheng G, et al:
Chemoresistance to 5-fluorouracil induces epithelial-mesenchymal
transition via up-regulation of Snail in MCF7 human breast cancer
cells. Biochem Biophys Res Commun. 417:679–685. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Haslehurst AM, Koti M, Dharsee M, et al:
EMT transcription factors snail and slug directly contribute to
cisplatin resistance in ovarian cancer. BMC Cancer. 12:912012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fojo T: Multiple paths to a drug
resistance phenotype: mutations, translocations, deletions and
amplification of coding genes or promoter regions, epigenetic
changes and microRNAs. Drug Resist Updat. 10:59–67. 2007.
View Article : Google Scholar
|
|
15
|
Chen GQ, Zhao ZW, Zhou HY, Liu YJ and Yang
HJ: Systematic analysis of microRNA involved in resistance of the
MCF-7 human breast cancer cell to doxorubicin. Med Oncol.
27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lian WJ, Liu G, Liu YJ, Zhao ZW, Yi T and
Zhou HY: Downregulation of BMP6 enhances cell proliferation and
chemoresistance via activation of the ERK signaling pathway in
breast cancer. Oncol Rep. 30:193–200. 2013.PubMed/NCBI
|
|
17
|
Wang Y and Shang Y: Epigenetic control of
epithelial-to-mesenchymal transition and cancer metastasis. Exp
Cell Res. 319:160–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kiesslich T, Pichler M and Neureiter D:
Epigenetic control of epithelial-mesenchymal-transition in human
cancer (Review). Mol Clin Oncol. 1:3–11. 2013.
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
|
|
20
|
Daibata M, Nemoto Y, Bandobashi K, et al:
Promoter hypermethylation of the bone morphogenetic protein-6 gene
in malignant lymphoma. Clin Cancer Res. 13:3528–3535. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hashida Y, Nemoto Y, Imajoh M, et al:
Promoter methylation of the bone morphogenetic protein 6 gene in
multiple myeloma. Oncol Rep. 27:825–830. 2012.PubMed/NCBI
|
|
22
|
Miyazono K, Maeda S and Imamura T: BMP
receptor signaling: transcriptional targets, regulation of signals,
and signaling cross-talk. Cytokine Growth Factor Rev. 16:251–263.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kersten C, Dosen G, Myklebust JH,
Sivertsen EA, Hystad ME, Smeland EB and Rian E: BMP-6 inhibits
human bone marrow B lymphopoiesis - upregulation of Id1 and Id3.
Exp Hematol. 34:72–81. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tamada H, Kitazawa R, Gohji K, Kamidono S,
Maeda S and Kitazawa S: Molecular cloning and analysis of the
5′-flanking region of the human bone morphogenetic protein-6
(BMP-6). Biochim Biophys Acta. 1395:247–251. 1998.
|
|
25
|
Barekati Z, Radpour R, Lu Q, et al:
Methylation signature of lymph node metastases in breast cancer
patients. BMC Cancer. 12:2442012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Taniguchi A, Nemoto Y, Yokoyama A, Kotani
N, Imai S, Shuin T and Daibata M: Promoter methylation of the bone
morphogenetic protein-6 gene in association with adult T-cell
leukemia. Int J Cancer. 123:1824–1831. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kimura K, Toyooka S, Tsukuda K, et al: The
aberrant promoter methylation of BMP3b and BMP6 in malignant
pleural mesotheliomas. Oncol Rep. 20:1265–1268. 2008.PubMed/NCBI
|
|
28
|
De Craene B and Berx G: Regulatory
networks defining EMT during cancer initiation and progression. Nat
Rev Cancer. 13:97–110. 2013.PubMed/NCBI
|
|
29
|
Shah AN, Summy JM, Zhang J, Park SI,
Parikh NU and Gallick GE: Development and characterization of
gemcitabine-resistant pancreatic tumor cells. Ann Surg Oncol.
14:3629–3637. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang AD, Fan F, Camp ER, et al: Chronic
oxaliplatin resistance induces epithelial-to-mesenchymal transition
in colorectal cancer cell lines. Clin Cancer Res. 12:4147–4153.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kajiyama H, Shibata K, Terauchi M,
Yamashita M, Ino K, Nawa A and Kikkawa F: Chemoresistance to
paclitaxel induces epithelial-mesenchymal transition and enhances
metastatic potential for epithelial ovarian carcinoma cells. Int J
Oncol. 31:277–283. 2007.
|
|
33
|
Hiscox S, Jiang WG, Obermeier K, et al:
Tamoxifen resistance in MCF7 cells promotes EMT-like behaviour and
involves modulation of beta-catenin phosphorylation. Int J Cancer.
118:290–301. 2006. View Article : Google Scholar : PubMed/NCBI
|
